A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer.

Trial Details

NCT ID
NCT06383767
Phase
PHASE3
Sponsor
Qilu Pharmaceutical Co., Ltd.
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • ESG401
  • Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • Individuals able to understand and give written informed consent.
  • Males or females aged ≥ 18 years ;
  • Histologically and/or cytologically confirmed HR+/HER2- breast cancer who had failed at least one line of systemic chemotherapy in metastatic setti…
  • Patients who are eligible for a chemotherapy regimen in the control group;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →